OMIX012596

1Summary
Title LPE18:1 drives clear cell renal cell carcinoma by stabilizing SIRT6 to reprogram lipid metabolism
Description ccRCC is characterized by profound lipid metabolic dysregulation, yet the mechanisms linking peritumoral PAT-derived lipid metabolites to tumor aggressiveness remain poorly defined. We identified LPE18:1, as a critical driver of tumor growth and lipid deposition. We demonstrated that LPE18:1 upregulates CAPZA1, which recruits USP48 to stabilize the SIRT6 . Increased SIRT6 epigenetically promotes ACAT2 expression, redirecting lipid metabolism toward free cholesterol accumulation-a hallmark of ccRCC aggressiveness. Genetic or pharmacological inhibition of the CAPZA1/SIRT6 axis can reverse LPE18:1-induced lipid deposition and tumor progression in xenograft models. Targeting this axis with the SIRT6 inhibitor OSS-128167 combined with CAPZA1 depletion significantly suppressed ccRCC cell growth. Our study reveals a PAT-derived lipid metabolite-fuelled signaling cascade that reprograms lipid metabolism in ccRCC, identifying CAPZA1/USP48/SIRT6 as actionable therapeutic targets for metabolic malignancies.
Organism Homo sapiens
Data Type Proteomic Data by Mass Spectrometry (MS)
Data Accessibility Controlled-access
BioProject PRJCA049522
Release Date 2026-01-02
Submitter Zhan Yang (yangzhan@hebmu.edu.cn)
Organization The Affiliated Hospital of Qingdao University
Submission Date 2025-10-29
2Files & Download

HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).

File ID File Title Number/Samples File Type File Size File Suffix Download
OMIX012596-01 shCON 3 Proteomic Data by Mass Spectrometry (MS) 4.51 GB tar Controlled
OMIX012596-02 shCAPZA1 3 Proteomic Data by Mass Spectrometry (MS) 4.57 GB tar Controlled
3Relevant Publications
Paper Title Journal Name Publish Time Accession Citing Type
Lysophosphatidylethanolamine 18: 1 drives clear cell renal cell carcinoma by stabilizing SIRT6 to reprogram lipid metabolism Signal Transduction and Targeted Therapy 2025-12 OMIX012675 OMIX012656 OMIX012596 Deposit

View All Released Data of OMIX